Halaman 1 dari 28 hasil
The present invention relates to pharmaceutically active naphthalene derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
Certain naphthalene derivatives are known to possess useful anti-flammatory activity and to be suitable for use in the treatment of
FIELD OF INVENTION
This invention relates to the filed of biotechnology. It describes an efficient bio-resolution process for the preparation of an anti-inflammatory drug S(+)-6-methoxy-.alpha.-methyl-2-naphthalene acetic acid (naproxen) of formula (2). Through the bio-resolution process, two
DETAILED DESCRIPTION OF INVENTION
1. Technical Field
The present invention relates to a tetrahydro-naphthalene derivative which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivative of the present invention has vanilloid receptor (VR) antagonistic
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a tetrahydro-naphthalene derivative which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivative of the present invention has vanilloid receptor (VR)
BACKGROUND OF THE INVENTION
The present invention relates to certain aryl substituted naphthalene, benzoxepine, benzazepine and benzocycloheptene derivatives.
SUMMARY OF THE INVENTION
The present invention relates to a compound having the structural formula I: ##STR1## or a pharmaceutically
Growth factors comprise a family of polypeptides with a manyfold of properties regulating for example cell proliferation and cell metabolism. As being multi-functional molecules, they may stimulate or inhibit cell proliferation as well as affect cell function depending on the type of the target
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention is concerned with the use of certain arylsulfonamides in the treatment of joint disease associated with chronic arthritis methods and pharmaceutical compositions therefore. In particular the invention is concerned with internal
DETAILED DESCRIPTION OF INVENTION
1. Technical Field
The present invention relates to a tetrahydro-naphthalene derivative which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivative of the present invention has vanilloid receptor (VR) antagonistic
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to amido substituted naphthalenes of general formula I: ##STR1## or their intermediates of general formula II: ##STR2## as described further below, and to a method for synthesizing the naphthalene derivatives. The
BACKGROUND OF THE INVENTION
This invention is directed to the treatment of certain dermatoses as well as inflammation associated with various diseases. It has been known to utilize the compound 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(alpha-methylstyryl)naphthalene which has the formula ##STR1##
The present invention relates to a new compound with anti-inflammatory, disinfectant and anti-bacterial activity, viz. (+)-6-methoxy-.alpha.-methyl-2-naphthalene acetate of N,N"-bis (4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraaza-tetradecan-diimidoamide, possessing the formula (T) ##STR2##
The
BACKGROUND
1. Field of the Invention
The present invention relates generally to a class of compounds derived from naphthalene, such as apogossypol and derivatives thereof, for treating a variety of disorders, diseases and pathologic conditions, and more specifically, for treating cancer, autoimmune
FIELD OF THE DISCLOSURE
The disclosure relates generally to a class of compounds derived from naphthalene, such as apogossypol and derivatives thereof, for treating a variety of disorders, diseases and pathologic conditions, and more specifically, for treating cancer, autoimmune diseases, and/or
FIELD OF THE DISCLOSURE
The disclosure relates generally to a class of compounds derived from naphthalene, such as apogossypol and derivatives thereof, for treating a variety of disorders, diseases and pathologic conditions, and more specifically, for treating cancer, autoimmune diseases, and/or
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed pursuant to 35 U.S.C. .sctn.371 as a United States National Phase Application of International Application No. PCT/EP2005/008763 filed 10 Aug. 2005, which claims priority from Great Britain Application No. 0418045.1 filed 12 Aug.